PT3134386T - Derivados de isoindolina-1-ona com atividade moduladora alostérica positiva para o recetor m1 muscarínico colinérgico para o tratamento da doença de alzheimer - Google Patents

Derivados de isoindolina-1-ona com atividade moduladora alostérica positiva para o recetor m1 muscarínico colinérgico para o tratamento da doença de alzheimer

Info

Publication number
PT3134386T
PT3134386T PT157263625T PT15726362T PT3134386T PT 3134386 T PT3134386 T PT 3134386T PT 157263625 T PT157263625 T PT 157263625T PT 15726362 T PT15726362 T PT 15726362T PT 3134386 T PT3134386 T PT 3134386T
Authority
PT
Portugal
Prior art keywords
alloesteric
isoindoline
derivatives
treatment
receptor positive
Prior art date
Application number
PT157263625T
Other languages
English (en)
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53276227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3134386(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PT3134386T publication Critical patent/PT3134386T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
PT157263625T 2014-04-23 2015-04-22 Derivados de isoindolina-1-ona com atividade moduladora alostérica positiva para o recetor m1 muscarínico colinérgico para o tratamento da doença de alzheimer PT3134386T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014089585 2014-04-23

Publications (1)

Publication Number Publication Date
PT3134386T true PT3134386T (pt) 2020-08-25

Family

ID=53276227

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157263625T PT3134386T (pt) 2014-04-23 2015-04-22 Derivados de isoindolina-1-ona com atividade moduladora alostérica positiva para o recetor m1 muscarínico colinérgico para o tratamento da doença de alzheimer

Country Status (36)

Country Link
US (16) US9315458B2 (pt)
EP (1) EP3134386B1 (pt)
JP (1) JP6517239B2 (pt)
KR (1) KR102349237B1 (pt)
CN (1) CN106536508B (pt)
AR (1) AR100154A1 (pt)
AU (1) AU2015250610B2 (pt)
BR (1) BR112016024472B1 (pt)
CA (1) CA2946519C (pt)
CL (1) CL2016002661A1 (pt)
CR (1) CR20160544A (pt)
CY (1) CY1123569T1 (pt)
DK (1) DK3134386T3 (pt)
DO (1) DOP2016000286A (pt)
EA (1) EA030373B1 (pt)
EC (1) ECSP16090152A (pt)
ES (1) ES2811088T3 (pt)
HR (1) HRP20201171T1 (pt)
HU (1) HUE050543T2 (pt)
IL (1) IL248393B (pt)
LT (1) LT3134386T (pt)
MX (1) MX2016013810A (pt)
MY (1) MY195742A (pt)
NZ (1) NZ725921A (pt)
PE (1) PE20161400A1 (pt)
PH (1) PH12016502095A1 (pt)
PL (1) PL3134386T3 (pt)
PT (1) PT3134386T (pt)
RS (1) RS60524B1 (pt)
SG (1) SG11201608785PA (pt)
SI (1) SI3134386T1 (pt)
TN (1) TN2016000455A1 (pt)
TW (1) TWI664165B (pt)
UA (1) UA122391C2 (pt)
UY (1) UY36091A (pt)
WO (1) WO2015163485A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014143768A1 (en) 2013-03-15 2014-09-18 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
BR112016024626B1 (pt) 2014-04-23 2023-03-21 Incyte Holdings Corporation Compostos 1h-pirrolo[2,3-c]piridin-7(6h)-onas e pirazolo[3,4-c]piridin-7 (6h)-onas, uso dos mesmos, composição farmacêutica que os compreende e método de inibição de uma proteína bet
JP6517239B2 (ja) * 2014-04-23 2019-05-22 武田薬品工業株式会社 アルツハイマー病治療のためのコリン作動性ムスカリンｍ１受容体ポジティブアロステリックモジュレーター活性としてのイソインドリン−１−オン誘導体
WO2015174534A1 (ja) 2014-05-16 2015-11-19 武田薬品工業株式会社 含窒素複素環化合物
EP3156397B1 (en) 2014-06-13 2019-08-07 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
EP3194406B8 (en) 2014-09-15 2021-03-31 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
EP3313836B1 (en) 2015-06-26 2020-11-11 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
JP6787913B2 (ja) 2015-10-20 2020-11-18 武田薬品工業株式会社 複素環化合物
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
WO2017107089A1 (en) * 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
EP3428150B1 (en) 2016-03-11 2023-07-12 Takeda Pharmaceutical Company Limited Aromatic ring compound having a cholinergic muscarine m1 receptor positive allosteric modulator activity
PE20190623A1 (es) 2016-06-20 2019-04-26 Incyte Corp Formas solidas cristalinas de un inhibidor de bet
WO2018005249A1 (en) * 2016-06-28 2018-01-04 Merck Sharp & Dohme Corp. Benzoisoquinolinone m1 receptor positive allosteric modulators
WO2018159639A1 (ja) 2017-02-28 2018-09-07 武田薬品工業株式会社 複素環化合物の製造方法
WO2018194181A1 (en) 2017-04-18 2018-10-25 Takeda Pharmaceutical Company Limited Heterocyclic compounds useful as modulators of acetylcholine receptors
JP7197472B2 (ja) * 2017-05-19 2022-12-27 武田薬品工業株式会社 スクリーニング方法
EP3634408B1 (en) * 2017-06-09 2022-12-28 Merck Sharp & Dohme LLC Azabicyclo[4.1.0]heptane allosteric modulators of the m4 muscarinic acetylcholine receptor
DK3643718T3 (da) 2017-06-20 2023-11-06 Takeda Pharmaceuticals Co Heterocyklisk forbindelse og anvendelse deraf som positiv allosterisk modulator af den kolinerge muskarin m1-receptor
EP3643718B1 (en) 2017-06-20 2023-07-26 Takeda Pharmaceutical Company Limited Heterocyclic compound and its use as positive allosteric modulator of the cholinergic muscarinic m1 receptor.
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) * 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) * 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
JP2020158392A (ja) * 2017-07-25 2020-10-01 Ａｇｃ株式会社 フルオロフェノール誘導体の製造方法及び新規なフルオロ化合物
CA3082724C (en) * 2017-11-23 2022-05-31 Suven Life Sciences Limited Substituted azacycles as muscarinic m1 receptor positive allosteric modulators
US20220041581A1 (en) 2018-09-28 2022-02-10 Takeda Pharmaceutical Company Limited Condensed-cyclic compound
EP3858828A4 (en) 2018-09-28 2022-07-06 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
JP7416537B2 (ja) 2018-09-28 2024-01-17 武田薬品工業株式会社 複素環化合物
WO2020139372A1 (en) * 2018-12-28 2020-07-02 Shui Yin Lo Method for detection treatment and prevention of neurological development disorders
EP4190770A1 (en) * 2020-07-29 2023-06-07 Vivozon, Inc. Dual regulator for mglur5 and 5-ht2a receptors and use thereof
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4416647Y1 (pt) 1965-05-26 1969-07-18
JPS60172704A (ja) 1984-02-14 1985-09-06 Mitsuwa Seiki Co Ltd 流体アクチユエ−タの制御方法
JP2699511B2 (ja) 1988-01-29 1998-01-19 武田薬品工業株式会社 置換アミン類
US5538983A (en) 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
TW219935B (pt) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
JPH06220044A (ja) * 1991-12-25 1994-08-09 Mitsubishi Kasei Corp ベンズアミド誘導体
GB9409150D0 (en) 1994-05-09 1994-06-29 Black James Foundation Cck and gastrin receptor ligands
US5744476A (en) 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
JP2992677B2 (ja) 1995-06-05 1999-12-20 武田薬品工業株式会社 骨形成促進医薬組成物
AU5716898A (en) 1997-01-08 1998-08-03 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
US7084126B1 (en) 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
JP2004502655A (ja) 2000-06-30 2004-01-29 イーライ・リリー・アンド・カンパニー 精神病の処置のための組み合わせ療法
CA2442717A1 (en) 2001-03-15 2002-09-26 Saegis Pharmaceuticals, Inc. Methods for restoring cognitive function following systemic stress
WO2002081446A1 (en) 2001-04-06 2002-10-17 Daewoong Co., Ltd. 3-cyclopentyloxy-4-methoxyphenyl-isoindolinone derivatives and the use thereof
WO2002081447A1 (en) 2001-04-06 2002-10-17 Daewoong Pharmaceutical Co., Ltd. 3-cyclopentyloxy-4-methoxyphenyl-isothiazolinone derivatives and the use thereof
US20040023951A1 (en) 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
DE10137163A1 (de) * 2001-07-30 2003-02-13 Bayer Ag Substituierte Isoindole und ihre Verwendung
US20040044023A1 (en) 2002-08-30 2004-03-04 Marc Cantillon Compositions and methods for treating or preventing memory impairment
WO2004073639A2 (en) 2003-02-19 2004-09-02 Merck & Co. Inc. Treatment of psychosis with a muscarinic m1 receptor ectopic activator
JP2006521399A (ja) 2003-03-28 2006-09-21 アカディア ファーマシューティカルズ，インコーポレーテッド 疼痛管理用ムスカリンｍ１受容体アゴニスト
US20040266659A1 (en) 2003-06-27 2004-12-30 Stephen LaBerge Substances that enhance recall and lucidity during dreaming
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
EP1874356A2 (en) 2005-04-15 2008-01-09 Board of Trustees of Michigan State University Aminergic pharmaceutical compositions and methods
US7868008B2 (en) 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US20110319386A1 (en) 2005-08-26 2011-12-29 Braincells Inc. Neurogenesis by muscarinic receptor modulation
WO2007044937A2 (en) 2005-10-13 2007-04-19 President And Fellows Of Harvard College Compositions and methods to modulate memory
GB0607952D0 (en) 2006-04-21 2006-05-31 Minster Res Ltd Novel treatment
GB0607946D0 (en) 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
GB0607949D0 (en) 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
TW200806625A (en) 2006-05-26 2008-02-01 Astrazeneca Ab Therapeutic compounds
US8143284B2 (en) 2006-10-05 2012-03-27 Abbott Laboratories Poly(ADP-ribose)polymerase inhibitors
US8618074B2 (en) 2007-03-15 2013-12-31 Board Of Regents Of The University Of Texas System GPCR enhanced neuroprotection to treat brain injury
US20090082388A1 (en) 2007-09-21 2009-03-26 Acadia Pharmaceuticals Inc. Co-administration of pimavanserin with other agents
US20090082342A1 (en) 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
US20090082368A1 (en) * 2007-09-24 2009-03-26 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
CA2700841A1 (en) * 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2010042603A1 (en) 2008-10-08 2010-04-15 Cingulate Neuro Therapeutics, Llc Amyloid and depression
CA2750708A1 (en) 2009-02-23 2010-08-26 Merck Sharp & Dohme Corp. Pyrazolo [4,3-c] cinnolin-3-one m1 receptor positive allosteric modulators
WO2010102218A1 (en) 2009-03-05 2010-09-10 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
US8877944B2 (en) 2009-07-14 2014-11-04 Nerviano Medical Sciences S.R.L. 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides as PARP inhibitors
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
HUE044653T2 (hu) 2009-07-22 2019-11-28 PureTech Health LLC Készítmények olyan rendellenességek kezelésére, amelyek muszkarin-receptor aktiválással enyhíthetõk
ES2842399T3 (es) * 2009-12-22 2021-07-14 Vertex Pharma Inhibidores isoindolinona de fosfatidilinositol 3-quinasa
US8314120B2 (en) * 2010-03-30 2012-11-20 Abbott Gmbh & Co. Kg Small molecule potentiators of metabotropic glutamate receptors
US8697690B2 (en) * 2010-07-01 2014-04-15 Merck Sharp & Dohme Corp. Isoindolone M1 receptor positive allosteric modulators
WO2012149524A1 (en) 2011-04-29 2012-11-01 The University Of Toledo Muscarinic agonists as enhancers of working memory and cognitive flexibility
US9206200B2 (en) 2011-05-17 2015-12-08 Merck Sharp & Dohme Corp. N-linked lactam M1 receptor positive allosteric mogulators
WO2012170599A1 (en) 2011-06-10 2012-12-13 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP3153167B1 (en) * 2011-10-28 2019-10-02 Vanderbilt University Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1
US9403802B2 (en) 2012-03-02 2016-08-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use therefor
US20130289019A1 (en) 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders
JP6211530B2 (ja) 2012-11-19 2017-10-11 武田薬品工業株式会社 含窒素複素環化合物
TW201512197A (zh) 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
BR112016006154A2 (pt) 2013-09-27 2017-08-01 Hoffmann La Roche derivados de indol e indazol
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
JP6517239B2 (ja) * 2014-04-23 2019-05-22 武田薬品工業株式会社 アルツハイマー病治療のためのコリン作動性ムスカリンｍ１受容体ポジティブアロステリックモジュレーター活性としてのイソインドリン−１−オン誘導体
WO2017044693A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
WO2018122845A1 (en) 2016-12-29 2018-07-05 Rvx Therapeutics Ltd. Methods and compositions for potentiating cns drugs and reducing their side effects

Also Published As

Publication number Publication date
SG11201608785PA (en) 2016-11-29
EA030373B1 (ru) 2018-07-31
EP3134386A1 (en) 2017-03-01
BR112016024472A8 (pt) 2021-06-29
US20170044143A1 (en) 2017-02-16
CN106536508B (zh) 2019-08-09
SI3134386T1 (sl) 2020-10-30
KR102349237B1 (ko) 2022-01-07
US20170258764A1 (en) 2017-09-14
US9315458B2 (en) 2016-04-19
CL2016002661A1 (es) 2017-03-24
US20150307451A1 (en) 2015-10-29
US9868725B2 (en) 2018-01-16
MX2016013810A (es) 2017-03-09
US20180346452A1 (en) 2018-12-06
US20190241547A1 (en) 2019-08-08
TN2016000455A1 (en) 2018-04-04
US20160152598A1 (en) 2016-06-02
DOP2016000286A (es) 2017-02-15
US10865200B2 (en) 2020-12-15
US9789083B2 (en) 2017-10-17
PE20161400A1 (es) 2017-01-06
US9655881B2 (en) 2017-05-23
UY36091A (es) 2015-11-30
US9789084B2 (en) 2017-10-17
CA2946519A1 (en) 2015-10-29
PL3134386T3 (pl) 2020-11-16
US20240109874A1 (en) 2024-04-04
EP3134386B1 (en) 2020-05-20
US10457670B2 (en) 2019-10-29
DK3134386T3 (da) 2020-08-17
UA122391C2 (uk) 2020-11-10
US20170266162A1 (en) 2017-09-21
CR20160544A (es) 2017-01-13
AU2015250610A1 (en) 2016-12-01
US20180000780A1 (en) 2018-01-04
US20170100384A1 (en) 2017-04-13
TW201623233A (zh) 2016-07-01
US9775827B2 (en) 2017-10-03
US9662316B2 (en) 2017-05-30
LT3134386T (lt) 2020-08-10
IL248393A0 (en) 2016-11-30
US20170100373A1 (en) 2017-04-13
EA201692132A1 (ru) 2017-04-28
US20220411413A1 (en) 2022-12-29
AR100154A1 (es) 2016-09-14
US9499516B2 (en) 2016-11-22
BR112016024472B1 (pt) 2023-02-14
US20160152603A1 (en) 2016-06-02
MY195742A (en) 2023-02-08
HUE050543T2 (hu) 2020-12-28
JP2017513894A (ja) 2017-06-01
HRP20201171T1 (hr) 2020-11-13
US9518042B2 (en) 2016-12-13
IL248393B (en) 2019-10-31
US9675597B2 (en) 2017-06-13
ES2811088T3 (es) 2021-03-10
CY1123569T1 (el) 2022-03-24
RS60524B1 (sr) 2020-08-31
US20170216255A1 (en) 2017-08-03
KR20160143852A (ko) 2016-12-14
AU2015250610B2 (en) 2019-02-07
WO2015163485A1 (en) 2015-10-29
US20210009572A1 (en) 2021-01-14
TWI664165B (zh) 2019-07-01
PH12016502095A1 (en) 2017-01-09
CN106536508A (zh) 2017-03-22
BR112016024472A2 (pt) 2017-08-15
JP6517239B2 (ja) 2019-05-22
CA2946519C (en) 2022-07-19
US20170027921A1 (en) 2017-02-02
ECSP16090152A (es) 2017-08-31
NZ725921A (en) 2023-09-29

Similar Documents

Publication Publication Date Title
IL248393A0 (en) Isoindoline-1-one derivatives for positive allosteric modulation activity for muscarinic 1m-cholinergic receptor for the treatment of Alzheimer's disease
HK1244802A1 (zh) 用於治療疾病的稠合雙環化合物
IL249065A0 (en) Combination of treatments for cancer treatment
EP3212233A4 (en) Combination therapy for treatment of disease
EP3180020A4 (en) Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
HK1245795A1 (zh) 用於治療疾病的稠合雙環化合物
IL249480A0 (en) Optogenetic treatments for movement disorders
EP3148532A4 (en) Pharmaceutical combination for the treatment of cancer
EP3140417A4 (en) Foetal polymix of mesenchymal stem cells under hypoxic conditions for the treatment of clinical disorders
LT3210973T (lt) Heteroarilo junginiai, skirti akių ligų gydymui
IL248779A0 (en) Pharmaceutical preparations for the treatment of infectious diseases
EP3137907A4 (en) Methods and compositions for the diagnosis and treatment of kawasaki disease
EP3169405A4 (en) Methods, compounds, and compositions for the treatment of musculoskeletal diseases
IL249502A0 (en) Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases
EP3100724A4 (en) Medicine for preventing ischemic diseases
EP3096775A4 (en) Socs mimetics for the treatment of diseases
SG11201702700UA (en) Methods for the treatment of peri-implantitis
EP3305263A4 (en) INTEGRATED BED FOR ORIENTAL MEDICINAL THERAPY
SG11201703330YA (en) Iminosugars useful for the treatment of viral diseases
PL3164110T3 (pl) Kompozycje farmaceutyczne do leczenia łuszczycy
PT2933251T (pt) Composição farmacêutica que pode ser utilizada para o tratamento de uma patologia do pé de um mamífero ungulado
AU2014902717A0 (en) Patients Bed
AU2014901666A0 (en) Medical bed
TWM490312U (en) Wheelchair bed structure